Licensing An Adjunct To In-House R&D, Not A Substitute – AstraZeneca Exec
Executive Summary
AstraZeneca views licensing and acquisitions as an add-on to, rather than a replacement for, internal research & development, Exec Director-Development John Patterson said Sept. 19